Clinical trials: Step
COPD
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to determine the safety and tolerability of single doses of QAB149 up to 3000 µg delivered via a single-dose, dry powder inhaler in patients with mild to moderate COPD.
- Trial name
- NCT00129831
- Testing
- QAB149
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Novartis
Chronic Pain, Low Back Pain
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release in subjects suffering from severe chronic low back pain (LBP) who are taking either WHO Step…
- Trial name
- NCT00983385
- Testing
- Tapentadol PR, Observation period
- Where
- 46 sites in Austria, Croatia and 7 more
- Volunteers
- 208 people
- Sponsor
- Grünenthal GmbH
Sepsis
Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects
This is a single-dose/multiple-doses incremental, randomized, double-blind, parallel, placebo-controlled study on safety, tolerance and pharmacokinetics healthy subjects.
- Trial name
- NCT04217629
- Testing
- SY-005
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Gastroenteropancreatic Neuroendocrine Tumor
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed…
- Trial name
- REAL-LU (NCT04727723)
- Testing
- Lutathera®
- Where
- 18 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS)
Next-Gen MS: Feed-forward PRO Data for MS Research
This Next Generation learning health system for Multiple Sclerosis (Next-Gen MS) study is a sub-study of the MS-LINK™ Outcomes Study (NCT04735406).
- Trial name
- NCT04907305
- Where
- 8 sites in United States
- Volunteers
- 1,594 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lumbar Spinal Stenosis
The STEPS - Totalis™ Trial
The purpose of this study is to determine safety and effectiveness, as measured by changes in pain, disability, patient satisfaction, and claudicatory symptoms, at 6 months following treatment with the Totalis™ Direct…
- Trial name
- NCT02079038
- Testing
- Totalis, Comparator Surgical Procedure
- Where
- 19 sites in United States
- Volunteers
- 180 people
- Sponsor
- VertiFlex, Incorporated
Pain
Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain
The main objective of the study is to evaluate the patient preference for pain treatment with respect to quality of life in patients with moderate to severe non malignant pain.
- Trial name
- NCT01167699
- Testing
- Oxycodone and naloxone
- Where
- Belgium
- Volunteers
- 174 people
- Sponsor
- Mundipharma Pharmaceuticals B.V.
Non Small Cell Lung Cancer
Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients with advanced NCLC not previously treated with systemic therapy.
- Trial name
- NCT00457119
- Testing
- RAD001
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Severe Asthma
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.
- Trial name
- TAPER (NCT07363642)
- Testing
- Tezepelumab
- Where
- 75 sites in China
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Asthma
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe.
- Trial name
- AIM4:Next Step (NCT06572228)
- Testing
- dupilumab, ICS/LABA
- Where
- 77 sites in United States, Canada and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404
This trial is a single-blind, cross-over design. Up to three patients with confirmed metastatic prostate adenocarcinoma and up to three healthy volunteers will receive two doses of 20.0 (± 3) mCi of intravenously administered…
- Trial name
- NCT01654874
- Testing
- 99mTc-MIP-1404
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Pain, Chronic Pain
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability
The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release in subjects suffering from severe chronic low back pain (LBP) who are taking WHO Step III…
- Conditions
- Pain, Chronic Pain, Low Back Pain, Neuropathic Pain
- Trial name
- NCT00986258
- Testing
- Tapentadol Prolonged Release
- Where
- 27 sites in Belgium, Czechia and 6 more
- Volunteers
- 136 people
- Sponsor
- Grünenthal GmbH
Asthma
Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA
The purpose of this phase IV Study is to compare the efficacy of CHF5993 (BDP/FF/GB 100/6/12.5 pMDI) on uncontrolled asthma subjects, versus CHF1535 (BDP/FF 200/6 pMDI).
- Trial name
- MiSTIC (NCT05018598)
- Testing
- Administration via pressurized metered dose inhaler (pMDI)
- Where
- Hungary
- Volunteers
- 320 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Parkinson Disease
A Clinical Study Trial of Phenlarmide in China
1. To evaluate the tolerance and safety of FLA tablets in healthy volunteers. 2. To evaluate the pharmacokinetics of FLA tablets in healthy volunteers. 3. Provide basis for dosage setting for follow-up clinical research.
- Trial name
- NCT04164121
- Testing
- Phenlarmide Tablets
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Yiling Pharmaceutical Inc.
Gastroesophageal Reflux Disease
Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC
A phase III, randomized, open-label, superiority study comparing the incremental product esomeprazole associated with sodium bicarbonate made by Eurofarma and Nexium® in the treatment of gastroesophageal reflux disease.
- Trial name
- NCT01471925
- Testing
- Nexium®, Esomeprazol (40mg) + Sodium Bicarbonate (721mg)
- Where
- 6 sites in Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Cancer Prevention
Step up to Health, Nigeria! Impact of 2022 World Cancer Day Walk on Health Behaviors Among Nigerians
Cancer awareness is a critical element of cancer prevention and control. Creating public awareness on risk factors, preventative strategies, and the importance of early screening is the foundation upon which a cancer control…
- Trial name
- NCT05239325
- Testing
- World Cancer Day Walk
- Where
- Nigeria
- Volunteers
- 527 people, healthy volunteers welcome
- Sponsor
- AshtaYoga, LLC
Multiple Sclerosis
Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS) and is one of the most common causes of neurological disability in young adults.
- Trial name
- NCT01195857
- Volunteers
- 100 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Moderate to Severe Allergic Asthma
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to assess the therapeutic potential and safety/tolerability of study drug (CYT003) at 3 dose levels versus placebo in patients with persistent moderate to severe allergic asthma not sufficiently…
- Trial name
- NCT01673672
- Testing
- CYT003
- Where
- 34 sites in United States, Czechia and 6 more
- Volunteers
- 365 people
- Sponsor
- Cytos Biotechnology AG
Asthma
Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma
The purpose of this study is to determine the effect of omalizumab, compared to placebo, on clinically significant asthma exacerbation rates in adolescents and adults with asthma.
- Trial name
- NCT00046748
- Testing
- Omalizumab
- Volunteers
- 484 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes
This trial is conducted in Europe, Africa and the United States of America (USA). The aim of this trial is to compare the safety and efficacy of two different insulin treatments, the "basic" and the "advanced" treatment in type 2…
- Trial name
- NCT00537303
- Testing
- insulin detemir, insulin aspart
- Where
- 69 sites in United States, Denmark and 10 more
- Volunteers
- 296 people
- Sponsor
- Novo Nordisk A/S